Title:
ANTI-CD27 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USE OF SAME
Document Type and Number:
WIPO Patent Application WO/2018/059465
Kind Code:
A1
Abstract:
An anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use of the same. Further, provided are a chimeric antibody comprising a CDR of the anti-CD27 antibody, a humanized antibody, a pharmaceutical composition comprising a human anti-CD27 antibody or an antigen-binding fragment thereof, and a use of the same as an anti-cancer drug. The present invention particularly relates to a human anti-CD27 antibody and a use thereof in preparing a drug for treating a CD27-mediated disease or disorder.
Inventors:
YAN SHUDE (CN)
JIANG JIAHUA (CN)
ZHANG LIANSHAN (CN)
CAO GUOQING (CN)
JIANG JIAHUA (CN)
ZHANG LIANSHAN (CN)
CAO GUOQING (CN)
Application Number:
PCT/CN2017/103842
Publication Date:
April 05, 2018
Filing Date:
September 28, 2017
Export Citation:
Assignee:
JIANGSU HENGRUI MEDICINE CO (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; A61P37/00; C12N1/15; C12N1/21; C12N5/10; C12N15/09; C12P21/08
Domestic Patent References:
| WO2016145085A2 | 2016-09-15 |
Foreign References:
| CN104284678A | 2015-01-14 | |||
| CN105669865A | 2016-06-15 | |||
| CN102007147A | 2011-04-06 | |||
| CN102918059A | 2013-02-06 |
Other References:
SAKANISHI, T. ET AL.: "Anti-tumor Effects of Depleting and Non-depleting Anti- CD 27 Monoclonal Antibodies in Immune-competent Mice", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 393, 18 February 2010 (2010-02-18), pages 829 - 835, XP026970765, DOI: doi:10.1016/j.bbrc.2010.02.092
HE, L. Z. ET AL.: "Agonist Anti-Human CD 27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD 27-Transgenic Mice", THE JOURNAL OF IMMUNOLOGY, vol. 191, 11 September 2013 (2013-09-11), pages 4174 - 4183, XP055496515, DOI: doi:10.4049/jimmunol.1300409
See also references of EP 3524624A4
HE, L. Z. ET AL.: "Agonist Anti-Human CD 27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD 27-Transgenic Mice", THE JOURNAL OF IMMUNOLOGY, vol. 191, 11 September 2013 (2013-09-11), pages 4174 - 4183, XP055496515, DOI: doi:10.4049/jimmunol.1300409
See also references of EP 3524624A4
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
Download PDF: